RT Journal Article
SR Electronic
T1 SARS-CoV-2 Delta variant of concern in Brazil - multiple introductions, communitary transmission, and early signs of local evolution
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.15.21262846
DO 10.1101/2021.09.15.21262846
A1 Patané, José
A1 Viala, Vincent
A1 Lima, Loyze
A1 Martins, Antonio
A1 Barros, Claudia
A1 Marqueze, Elaine
A1 Bernardino, Jardelina
A1 Moretti, Debora
A1 Slavov, Svetoslav
A1 Bezerra, Rafael
A1 Rodrigues, Evandra
A1 Santos, Elaine
A1 Brassaloti, Ricardo
A1 Cassano, Raquel
A1 Mariani, Pilar
A1 Kitajima, João
A1 Santos, Bibiana
A1 Assato, Patricia
A1 Costa, Felipe
A1 Poleti, Mirele
A1 Lesbon, Jessika
A1 Chicaroni, Elisangela
A1 Banho, Cecilia
A1 Sacchetto, Lívia
A1 Moraes, Marília
A1 Palmieri, Melissa
A1 Vilanova, Fabiana
A1 Martininghi, Maiara
A1 Grotto, Rejane
A1 Souza-Neto, Jayme
A1 Giovanetti, Marta
A1 Alcantara, Luiz
A1 Nogueira, Maurício
A1 Fukumasu, Heidge
A1 Coutinho, Luiz
A1 Calado, Rodrigo
A1 Kashima, Simone
A1 Neto, Raul
A1 Covas, Dimas
A1 Elias, Carolina
A1 Coccuzzo, Sandra
YR 2021
UL http://medrxiv.org/content/early/2021/10/12/2021.09.15.21262846.abstract
AB The dissemination of the Delta VOC in Brazil is still unclear, despite the frequent reports of isolated cases from different Brazilian states. In this report we characterize the dissemination of the Delta VOC in Brazil and where the introductions of this lineage fall within the global Delta phylogeny. We also examined the mutational profile of the largest clade within the Brazilian Delta VOCs, with a focus on samples which were obtained in the State of São Paulo, and especially in the city of São Paulo, the largest metropolis of South America, and a national and international transportation hub.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCAAE: 50367721.7.1001.5440Funding StatementButantan Foundation, Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Grant Numbers: 2020/10127; 2020/06441-2), Fundacao Hemocentro Ribeirao Preto, Pan American Health Organization (OPAS)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Ethics Committee of the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo (CAAE: 50367721.7.1001.5440).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI am making available all data referred to in the manuscript in the form of tables (either regular os supplementary).